Since the beginning, the Institut Pasteur de Lille has been a research institute of excellence dedicated to infectious diseases. It has always combined basic aspects of science with potential applications. The first major success was the development of the Bacillus Calmette-Guérin (BCG) by the first General Director of the Institute, Albert Calmette, and his co-worker Camille Guérin. BCG is the most widely used vaccine in the world and is still the only vaccine available against tuberculosis and leprosy.
During the last decades, the research topics of the Institut Pasteur de Lille have evolved in broader research areas, including parasitology, virology, bacteriology and immunology, as well as cancer and cardiovascular and neurodegenerative diseases. In 2009, the teams involved in infectious diseases and immunity decided to combine their efforts and create the "Center for Infection and Immunity of Lille" (CIIL). This center has officially been launched on January 1st 2010 as a mixed research unit of the Institut Pasteur de Lille, Inserm (U1019), CNRS (UMR 8204) and the Lille University.
63 Engineers, Technicians,
14 Master students
33 PhD students
27 Post-Docs/ Researchers